745 related articles for article (PubMed ID: 15896547)
1. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
Wolf R; Matz H; Marcos B; Orion E
Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
[TBL] [Abstract][Full Text] [Related]
2. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
3. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS.
Viera MH; Perez OA; Patel JK; Jones I; Berman B
Cutis; 2010 Jun; 85(6):312-7. PubMed ID: 20666193
[TBL] [Abstract][Full Text] [Related]
4. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
Sane SP; Bhatt AD
J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
[TBL] [Abstract][Full Text] [Related]
5. Life-threatening acute adverse cutaneous drug reactions.
Wolf R; Orion E; Marcos B; Matz H
Clin Dermatol; 2005; 23(2):171-81. PubMed ID: 15802211
[TBL] [Abstract][Full Text] [Related]
6. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.
Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T
Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378
[TBL] [Abstract][Full Text] [Related]
7. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS.
Darlenski R; Kazandjieva J; Tsankov N
Clin Dermatol; 2015; 33(5):538-41. PubMed ID: 26321400
[TBL] [Abstract][Full Text] [Related]
8. Drug Rash with eosinophilia and systemic symptoms versus Stevens-Johnson Syndrome--a case that indicates a stumbling block in the current classification.
Wolf R; Davidovici B; Matz H; Mahlab K; Orion E; Sthoeger ZM
Int Arch Allergy Immunol; 2006; 141(3):308-10. PubMed ID: 16940741
[TBL] [Abstract][Full Text] [Related]
9. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking.
Walsh SA; Creamer D
Clin Exp Dermatol; 2011 Jan; 36(1):6-11. PubMed ID: 21143513
[TBL] [Abstract][Full Text] [Related]
10. Approach to the patient with a suspected drug eruption.
Cotliar J
Semin Cutan Med Surg; 2007 Sep; 26(3):147-54. PubMed ID: 18070681
[TBL] [Abstract][Full Text] [Related]
11. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions.
Hirahara K; Kano Y; Mitsuyama Y; Takahashi R; Kimishima M; Shiohara T
Clin Exp Dermatol; 2010 Dec; 35(8):863-8. PubMed ID: 20456395
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
[TBL] [Abstract][Full Text] [Related]
13. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
Watanabe R; Watanabe H; Sotozono C; Kokaze A; Iijima M
Eur J Dermatol; 2011; 21(6):889-94. PubMed ID: 21873140
[TBL] [Abstract][Full Text] [Related]
14. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
15. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
[TBL] [Abstract][Full Text] [Related]
16. [Cutaneous reactions to drugs].
Mulder WM; Meinardi MM; Bruynzeel DP
Ned Tijdschr Geneeskd; 2004 Feb; 148(9):415-20. PubMed ID: 15038200
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications.
Sotozono C; Ueta M; Koizumi N; Inatomi T; Shirakata Y; Ikezawa Z; Hashimoto K; Kinoshita S
Ophthalmology; 2009 Apr; 116(4):685-90. PubMed ID: 19243825
[TBL] [Abstract][Full Text] [Related]
18. [Severe delayed drug hypersensitivity reactions].
Maniu CM; Buss G; Feldmeyer L; Spertini F; Ribi C
Rev Med Suisse; 2013 Apr; 9(382):803-4, 806-11. PubMed ID: 23667969
[TBL] [Abstract][Full Text] [Related]
19. Differential diagnosis of severe cutaneous drug eruptions.
Bachot N; Roujeau JC
Am J Clin Dermatol; 2003; 4(8):561-72. PubMed ID: 12862499
[TBL] [Abstract][Full Text] [Related]
20. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis.
Rzany B; Hering O; Mockenhaupt M; Schröder W; Goerttler E; Ring J; Schöpf E
Br J Dermatol; 1996 Jul; 135(1):6-11. PubMed ID: 8776350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
